

tag2009

PROGRESS IN THE FIGHT FOR BETTER TREATMENT, A VACCINE, AND A CURE FOR AIDS

Dear Friends of TAG,

This annual report for 2009 highlights many of the accomplishments of Treatment Action Group throughout the year (see 2009 at a Glance).

The year 2009 was a challenging one for AIDS activism. Yet with a staff of only ten people, TAG continues to expand its influence within the epidemic by shaping community and global thinking around critical issues such as when to initiate antiretroviral therapy, improving the safety and relevance of clinical trials to people with HIV and its most common coinfections—tuberculosis and viral hepatitis—ensuring more money is allocated to research and treatment, and closely monitoring the potential of antiretroviral treatment as part of a comprehensive HIV prevention approach.

Here in New York, the nonprofit sector felt the acute impact of the financial

crisis throughout 2009. Many of our peers at other nonprofits eliminated staff and reduced salaries, but the vigilance of our board of directors and the prudent spending of TAG staff allowed us to keep our programs intact. Despite the challenges of last year, TAG is stronger than ever.

TAG is a small but powerful organization—our staff members work with some of the best HIV, hepatitis, and TB researchers; they consult with the most powerful global health institutions; they collaborate with other powerful activist organizations. This all serves to drive better research and treatment toward a vaccine and cure for AIDS.

Your commitment to funding TAG's work ensures that we can maintain our unique ability to unite key global health institutions, researchers and scientists, community activists and

WHAT'S INSIDE

- 2009 at a Glance
- TAG Projects
- TAG Limited Edition 2009
- Contributors 2009
- The Palm Donor Circle
- TAG Financials 2009

policy makers to bring about the highest impact to curb and eventually end the HIV epidemic.

Please give generously. TAG will work tirelessly until the epidemic is over. Until then, we need your support. Thank you.

Barbara Hughes
President, Board of Directors



Barbara Hughes (left), and Mark Harrington (third from left) with RIAA honorees (left to right): David Hyde Pierce, Dr. Michel Kazatchkine, Dr. Roy "Trip" Gulick, Simon Doonan

Research in Action Awards 2009

Treatment Action Group's 2009 Research in Action Awards honored Dr. Michel Kazatchkine; columnist, author, and creative director for Barneys, Simon Doonan; Dr. Roy "Trip" Gulick; and Tony and Emmy winning actor David Hyde Pierce.

TAG's 2009 Research in Action Awards in New York City honored individuals who have made a significant contribution to AIDS research and activism.

This year's honorees included **Dr. Michel Kazatchkine**, executive director of the Global Fund to Fight AIDS, TB and Malaria; author and columnist **Simon Doonan**; Cornell University's **Dr. Roy "Trip" Gulick**, a pioneer in combination therapy, which has become the standard

of care for people with HIV; and actor **David Hyde Pierce**, who has won both Tony and Emmy Awards. **Jenna Wolfe** from the *Weekend Today* show hosted the event with grace and humor. **David Rakoff's** hilarious introduction of **Trip Gulick** was a highlight of the evening and David Hyde Pierce's acceptance speech reminded us of times and people that keep all of us engaged in the struggle to end the AIDS epidemic.

2009 AT A GLANCE

JANUARY

TAG sends recommendations to newly inaugurated president **Barack Obama** on AIDS research and treatment policy urging the new administration to demonstrate strong domestic and global leadership and to strengthen AIDS research. TAG submits recommendations to the National Institute for Allergy and Infectious Diseases (NIAID) on speeding up research toward a cure for HIV.

FEBRUARY

TAG's staff and board spend two days intensively brainstorming about the organization's strategic priorities and plans for the next four years (2009–2012). TAG Antiretroviral Project director **Bob Huff** and Basic Science Project coordinator **Richard Jefferys** are interviewed at AIDSmeds.com to discuss HIV therapies to watch in 2009.

MARCH

TAG publishes *Flat-Lined: How Flat NIH Funding Undermines Research on HIV, TB, and Viral Hepatitis*. The report provides a comprehensive picture of the state of U.S. National Institutes of Health (NIH) research investment in HIV/AIDS, hepatitis B, hepatitis C, and tuberculosis (TB). Documenting five years of flat research funding (2004–2009), the report is used to advocate for increased funding for the NIH. TAG's Hepatitis/HIV Project director **Tracy Swan** delivers the plenary speech at the New York State Hepatitis C Conference on the drugs in development for hepatitis C virus (HCV) infection. Tracy presents on HCV treatment, research, and costs at the Open Society Institute (OSI) meeting on scale-up of HCV treatment in Kiev, Ukraine. **Lei Chou**, TAG's HIV/Hepatitis Project coordinator, discusses drug company assistance programs to improve patient access to treatment for viral hepatitis at AIDSmeds.com.



2009 Research in Action Award honoree **David Hyde Pierce** discusses the importance of remembering

TAG executive director **Mark Harrington** and **Javid Syed**, TB/HIV project director, collaborate with **Médecins sans Frontières** and **Partners in Health** to accelerate research for a point-of-care TB diagnostic that could be used in field settings.

APRIL

Biotechnology company **Bionor Immuno** changes its clinical trial screening process as a result of **Richard Jefferys** writing to the company raising the importance of screening for cardiovascular disease risk in their therapeutic vaccine/treatment interruption trial. The company responds by adding EKG and stress tests to the trial screening process and excluding persons with a history of heart problems from the trial. TAG writes to NIAID director **Dr. Anthony S. Fauci** expressing opposition to a planned HIV vaccine trial, HVTN 505. NIAID acknowledges TAG's concerns and provides an extensive explanation why they believe the trial is scientifically important. TAG policy director **Sue Perez** mobilizes nearly 200 signatures from civil society organizations worldwide for the letter that she personally delivers to **Dominique Strauss-Kahn**, managing director of the International Monetary Fund calling for policy reforms to support poor countries' efforts to scale up investments and access to quality health and education.

MAY

TAG criticizes President Obama's first budget for its inadequate support of AIDS research, prevention, and treatment, noting that "**Obama's global, domestic, HIV research budgets leave a trail of shredded promises in their wake.**" The *International Journal of Tuberculosis and Lung Disease* publishes "How Research Can Help to Control Tuberculosis," written by **Richard Chaisson** of the Johns



Coco Jervis, senior policy associate and **Claire Wingfield**, assistant director of the TB/HIV Project

Hopkins University and TAG's **Mark Harrington**, who delivers the keynote lecture on TB and activism at the Johns Hopkins University Center for TB Research annual meeting in Baltimore. **Claire Wingfield**, assistant director of TAG's TB/HIV Project, testifies at an U.S. Food and Drug Administration (FDA) Advisory Committee meeting on the urgency of developing effective new therapies to treat drug-resistant and pediatric tuberculosis. TAG staff meet with **Dr. Anthony S. Fauci** and the heads of the divisions of AIDS and microbiology to discuss transforming the NIAID-supported HIV research networks into broader platforms including support for research on tuberculosis and viral hepatitis. This meeting leads to a commitment by NIAID to expanding TB clinical trials by \$9 million in 2010. The AIDS Vaccine Advocacy Coalition, TAG, and the Global HIV Vaccine Enterprise cohost a forum featuring community and scientific panels to discuss the future of AIDS research. **Tracy Swan** and **Lei Chou** successfully conclude a two-year collaboration with the Thai Treatment Action Group with a five-day viral hepatitis train-the-trainer workshop using a community-informed curriculum, written by Tracy and Lei, for Thai treatment activists. The curriculum has been translated into English and Chinese and is being adapted for an American audience. TAG expands its policy team by hiring **Coco Jervis**, J.D.—an experienced policy activist—to bolster TAG's policy program.

JUNE

The Guide to Hepatitis B for People Living with HIV, written by **Lei Chou**, was published and distributed to New York-based hepatitis providers and gastroenterologists, AIDS drug assistance program administrators, state viral hepatitis directors, and AIDS service community groups. The publication goes into a second printing due to high demand. **Coco Jervis** attends a stakeholders' meeting with FDA commissioner **Margaret Hamburg**



2009 Research in Action Award honoree **Dr. Trip Gulick** remembers the discovery of effective HIV combination therapy

to outline TAG's priorities on clinical trials and regulatory issues for HIV, TB, and viral hepatitis. Commissioner Hamburg provides positive feedback and expresses her "profound admiration for the work TAG has done over the years."

JULY

The journal *Hepatology* publishes changes in hepatitis C treatment guidelines based on guidance from TAG's **Tracy Swan**, while her article "Adherence to Medication for Hepatitis C—Building on the Model of HIV Adherence Research" is published in *Alimentary Pharmacology and Therapeutics*. **Claire Wingfield** makes recommendations to the European Union on their TB/HIV research and funding priorities. **Sue Perez** organizes a coalition of U.S.-based nongovernmental organizations (NGOs) that leads to the establishment of a unified movement for health financing. At the Fifth International AIDS Society Conference on HIV, Pathogenesis, Treatment and Prevention in July, TAG cosponsors the meeting "Catalyzing HIV/TB Research: Innovation, Funding, and Networking," at which NIAID Director **Dr. Anthony S. Fauci** quotes TAG's TB research tracking report in his keynote speech. **Mark Harrington** gives a keynote speech on HIV and TB activism titled "From HIV to TB and Back Again: A Tale of Activism in Two Pandemics." TAG releases its signature publication, the *TAG 2009 Pipeline Report*.

AUGUST

TAG is awarded a new two-year grant for the **HIV/Hepatitis Coinfection Project** from the **Levi Strauss Foundation**. In partnership with MSF India at the International Conference on AIDS in Asia and the Pacific, **Javid Syed** organizes a session to highlight how AIDS organizations have successfully implemented TB control methods to reduce TB infection among people living with HIV.

SEPTEMBER

Mark Harrington joins the peer-review team to update World Health Organization (WHO) guidelines for earlier HIV treatment initiation. The updated, more aggressive treatment guidelines are published worldwide in December 2009. Mark also works with the WHO and the Stop TB Partnership to rewrite and rebudget the research and development sections for the Global Plan to Stop TB. **Sue Perez** attends a meeting on the U.S. national HIV/AIDS strategy and cochairs a breakout session on research; resulting recommendations are presented to the White House Office of National AIDS Policy. **Sue Perez** collaborates with NGOs to issue a press release, "U.S. Global AIDS Program at Risk of Dwindling under New Leadership," calling for stronger presidential leadership on global AIDS.

OCTOBER

Long awaited results of the Thai vaccine trial RV 144 are published, suggesting a marginal benefit. TAG's **Richard Jefferys** authors several blog posts analyzing and critiquing the presentation of the data, along with a comprehensive article on the study for *TAGline*. TAG hosts a community forum at the TAG offices called "HIV Treatment Now," featuring doctors **Roy "Trip" Gulick** and **Marshall Glesby** from New York-Presbyterian Hospital/Weill Cornell Medical Center. **Sue Perez** spearheads the development of a report with a coalition of advocacy groups titled *The Future of Global Health: Ingredients for a Bold and Effective U.S. Initiative*, which presents a comprehensive blueprint for global health with clear targets, funding levels, and policy reforms that are needed. **Coco Jarvis** presents TAG's perspective to a WHO-sponsored task force on ethical issues in TB control.

NOVEMBER

The 2009 Report on Tuberculosis Research Funding Trends, 2005-2008 by TAG in

partnership with the Stop TB Partnership is released at the International Union against TB and Lung Disease. **Mark Harrington's** article "Community Involvement in HIV and Tuberculosis Research" is published in the *Journal of Acquired Immune Deficiency Syndromes*. **Tracy Swan** works with the European AIDS Treatment Group to sponsor a two-day workshop on access to experimental hepatitis C drugs for people coinfecting with HIV that was attended by community members, U.S. and European regulators, representatives from pharmaceutical companies, and researchers. A consensus statement and report from the meeting will be released in April 2010.

DECEMBER


TAG and the International Community of Women Living with HIV-East Africa (ICW) publish *Empowering Communities for TB Advocacy: The TAG-ICW Model*. The publication serves as a blueprint to empower people with HIV, TB patients, and their communities to work for effective program implementation in their countries and to reduce the burden of TB among people with HIV. TAG's **Lei Chou** is chosen as the new community representative on the U.S. government adult and adolescent HIV treatment guidelines panel. **Lei Chou** and **Tracy Swan** present their poster "Do the Right Thing: Eliminating Racial Disparities in Viral Hepatitis Drug Development" at the HEP DART (development of therapies for viral hepatitis) meeting. TAG's annual Research In Action Awards (RIAA) event honors researcher **Dr. Roy "Trip" Gulick**, actor **David Hyde Pierce**, executive director of the Global Fund to fight HIV, TB and Malaria **Dr. Michel Kazatchkine**, and writer/activist **Simon Doonan**. **David Gold** of Global Health Strategies chairs the RIAA committee and **Jenna Wolfe** of *Weekend Today* emcees the festivities, which raise \$150,000 for TAG's work.



Simon Doonan, author and style personality, Mark Harrington, TAG's executive director, Regan Hoffman, editor-in-chief of POZ magazine



Jenna Wolfe of the *Weekend Today* show hosts the awards



Mark Harrington, TAG executive director; 2009 Research in Action Award honoree Dr. Michel Kazatchkine, executive director of the Global Fund to Fight AIDS, TB and Malaria; and Robin Gorna, executive director of the International AIDS Society

TAG PROJECTS

The Antiretroviral Project

TAG's Antiretroviral Project closely monitors and influences the state of research on anti-HIV drug discovery, development, dissemination, and postmarketing surveillance; advocates for accelerated, better-focused efforts in this area; and focuses on innovative treatments for drug-resistant HIV that are easier to take, less toxic, and/or represent a major therapeutic breakthrough. TAG advocates for better postmarketing research on approved antiretroviral drugs to improve standards of care; works on domestic and international treatment guidelines; and educates and mobilizes policy makers, researchers, and the HIV community on anti-HIV treatment research. TAG works with academic researchers, clinicians, the Food and Drug Administration (FDA) and the National Institutes of Health (NIH), and with domestic and international community coalitions to achieve these ends. TAG also works to catalyze research to understand and eventually defeat HIV persistence in the body and advocates for intensified efforts to cure HIV infection.

The Michael Palm HIV Pathogenesis and Prevention Project

TAG's Palm Project works to improve the state of basic research on HIV/AIDS, including pathogenesis, immunology, vaccine, microbicide, and preclinical discovery and development. The Palm Project advocates for better and faster research into the pathogenesis of HIV infection and the interactions between HIV and the immune system; for research on immune-based therapeutic approaches to HIV infection; for accelerated, scientifically rigorous HIV vaccine and microbicide research; and on projects to educate and mobilize policy makers, researchers, and the HIV community on basic science and vaccine development.



**Regan Hofmann, editor-in-chief
of POZ magazine**


The Hepatitis/HIV Project

TAG's Hepatitis/HIV Project works to increase the length and quality of life among people living with HIV. Hepatitis B virus (HBV) and hepatitis C virus (HCV) are common—and deadly—coinfections of HIV, although both are treatable. In fact, liver disease is now cited as a leading cause of death among HIV-positive people in the United States and Western Europe. The Hepatitis/HIV Project works domestically and globally to broaden access to and improve quality of care and treatment for viral hepatitis coinfection. TAG advocates for research on prevention, treatment, and health care delivery systems, oversees viral hepatitis and HIV drug development, and educates and mobilizes the HIV community, policy makers, and researchers to fight viral hepatitis coinfection.

The TB/HIV Advocacy Project

The aim of TAG's TB/HIV Advocacy Project is to create an effective response to the challenges posed by the intersecting epidemics of tuberculosis (TB) and HIV by increasing research for new tools for TB/HIV and the utilization of those tools to achieve universal access to quality TB/HIV services. The project works with community advocates and key decision makers to emphasize the need for urgent action to improve our understanding of TB basic science, research for TB tools, TB/HIV programs and policies both domestically and internationally.

Worldwide, TB is the leading cause of death among people living with HIV. As such, TAG leads the creation of demand and an effective response to increase quality and quantity of research, programs, and funding available to combat the two epidemics of TB and HIV.



**Dr. Michel Kazatchkine, the executive
director of the Global Fund to Fight
AIDS, Tuberculosis and Malaria**

The U.S. and Global Health Policy

The U.S. and Global Health Policy Project advocates for responsible U.S. government policies and adequate funding to achieve universal access to comprehensive AIDS, TB, and viral hepatitis services in the United States and around the world. TAG also works to ensure high U.S. political commitment and investment in research and development for AIDS, TB, and viral hepatitis. TAG maximizes partnerships with U.S. and global health advocates and activists to inform and affect political decision making. In 2009, TAG hired Coco Jervis as senior policy associate to support policy director Sue Perez, and to lead TAG's domestic policy advocacy efforts in Washington, D.C.

TAG Limited Edition 2009

Donald Moffett, *Enlarged
Hypothalamus*, 2009

Each year at its annual Research in Action Awards ceremony, TAG presents a new limited-edition artwork, generously donated by a highly regarded visual artist.

Contributing artists have included Tony Feher, Carrie Yamaoka, David Armstrong, Richard Renaldi, and Ben Thornberry.

Examples of artworks offered at past Research in Action Awards ceremonies may be viewed on our website and can be purchased by contacting TAG at 212.253.7922.



**Artist Donald Moffett and *Enlarged
Hypothalamus*, this year's Limited
Edition offering**

CONTRIBUTORS 2009

\$100,000 OR MORE

The Bill & Melinda Gates Foundation
The Michael Palm Foundation
National Institutes of Health, Office of AIDS Research

\$50,000—\$99,999

John M. Lloyd Foundation
World Health Organization/Stop TB Partnership

\$25,000—\$49,999

Gilead Sciences, Inc.
GlaxoSmithKline
Levi Strauss Foundation
Merck & Co., Inc.
Newman's Own Foundation
Roche/Hoffmann-LaRoche Pharmaceuticals Inc.
Schering-Plough Corporation
Tibotec Therapeutics

\$10,000—\$24,999

Bristol-Myers Squibb Company
Broadway Cares/Equity Fights AIDS
City of New York/New York City Council
Elton John AIDS Foundation
Gesso Foundation
Global Health Strategies
RESULTS Educational Fund

\$5,000—\$9,999

A|X Armani Exchange
David Corkery
Nicholas A.R. Debs
Mitchell Gold + Bob Williams
The Hargrove Pierce Foundation "In Honor of Mike Nichols"
Stephen Mack & Robert Monteleone
Rainbow Endowment
James Saakvitne & Daniel Chow
Andrew David Zacks/The Zacks Family Foundation

\$2,500—\$4,999

Boehringer Ingelheim Pharmaceuticals Inc.
Marcus Edward & Ken O'Neill
M. Lee Garrison
Richard M. Lynn & Joseph Evall
Alby P. Maccarone, Jr.
Stuart & Linda Nelson "In Honor of Fred Hersch"
SMS Talent Inc. & The Safran Company

\$1,000—\$2,499

Aeras Global TB Vaccine Foundation
AIDS Global Action
Alzheimers Association, NYC Chapter
Anonymous
Henry H. Arnhold/The Arnhold Foundation
BBMG Entertainment Group
Carl Berg PhD & Judith Green PhD
Helen Bodian & Roger Alcala
Timothy & Mary C. Casey
Edgar M. & Elissa F. Cullman
Richard A. & Barbara Knowles Debs/The Debs Foundation
"A Diamond Is Forever"/Sally Morrison
Randall G. Drain
f u s e/Madison Square Garden
Dr. Michael F. Giordano
Steven & Judith O. Gluckstern/The Lucky Star Foundation
Agnes Gund/The A G Foundation
William Haber
Judith & Richard Harrington
Florette B. Hoffheimer Fund of Johnson Charitable Gift Fund
Barbara F. Hughes & Andrea Benzacar Dailey

International AIDS Vaccine Initiative
Horace S. "Chad" Kenney III
Noel E.D. Kirnon & Michael D. Paley
James S. & Ellen Marcus
Barry Margolin "In Memory of Paul F. Sherman"
Médecins Sans Frontières
Terence S. & Emily Souvaine Meehan
Kenneth T. Monteiro & Leo J. Blackman
Kent & Ann Morgan "In Honor of Fred Hersch"
Jason I. Osher & Richard R. Schubel
Andrew & Andrea Potash
Walter Rieman
David Saylor & Charles Kreloff "In Memory of Robert Polenz"
Dr. Bruce R. Schackman & Edward K. Sikov
Evan Schwartz & Robert Fitterman
Marvin Shulman
David Sigal & Brad Hoylman
Gerald & Ellen Sigal
Frank E. Spring & Darrel Frost
Monte Steinman
W. Kirk Wallace & Mark M. Sexton Fund of Stonewall Community Foundation
The Terry K. Watanabe Charitable Trust
Weill Cornell Medical College
Simon Yates & Kevin Roon

\$500—\$999

AIDS Vaccine Advocacy Coalition/Mitchell Warren
Robert L. Aldridge
American Jewish World Service
Benjamin, Christine & Darius Anagnos
Kevin Goetz & Neil Dick Goetz
Katheine C. & Thomas M. Ash III
Professor Rifat Atun
Lindsay Barenz
Becton Dickinson
Elizabeth Bennett & Sara Luther
Jonathan & Ann Binstock/The Binn Family Foundation
Eli & Jalile Camhi
Arianne Dar
Sarah Lynn Deming "In Memory of Mike Deming"
Dinowitz & Bove
Hon. Thomas K. Duane & Louis Webre
Joy Episalla & Carrie Yamaoka
Steven M. Frank & Dr. Elizabeth Powell
Charles E. Hamlen "In Honor of Scott Morgan & Fred Hersch"
Mark Harrington
Craig Hempstead & John Ricotta
Henry J. & Sharon Y. Hersch
James C. Hormel
"In Honor of Simon Doonan"
Kevin B. Jennings & Jeff Davis
Lee Jones
John Kander
Paul E. Kennedy & John Marsh
Lee & Daney Klingenstein Fund
Mathilde Krim PhD
Winston B. Layne
Dan Lilley
Michael K. Longacre
Carey C. Maloney & Hermes Mallea
Anthony Meier Fine Arts/Anthony & Celeste Meier
Florent G. Morellet & Peter Cameron
Mirla & George Morrison
Leslie Fay Pomerantz
Andrew & Julie Sacks
Marja Samson/The Kitchen Club
Michael Schmidt & Teri Rydl
Lynne T. Smalley
Dr. Achilles O. Stachtariar, Jr.
Peter Staley & Gary Schwartz

Michael R. Stinchcomb
Barbara Tfunk
Joan Vail Thorne
Joseph F. Tringali
United Way
Paul F. Walter
William J. Zwart & David Berchenbriter

\$250—\$499

Jeffrey Arnstein & Michael Field
Awearness Fund/Kenneth Cole
Gregory W. Bartha MD
Jamie Bernstein
Jerome Blake
Prof. Richard M. Buxbaum & Catherine B. Hartshorn
Dr. & Mrs. Charles C.J. Carpenter
Mrs. Denise B. Dailey
Scott Dainton
Edward J. Davis & Thomas D. Phillips
Peter Morris Dixon
Douglas O. Drake
Ivy & Marc Duneier
Alan E. Farley
Tony Felzen "In Honor of Brad Hoylman & David Sigal"
Hartly Fleischmann
Kenneth Fornataro
Kenneth L. Geist
Jo L. & Bill Hamilton
Dr. Marjorie J. Hill
Jay Jasper
Cindy Kleine
Charles L. & Louise Marburg "In Honor of Fred Hersch"
F. Joseph McConnell & Erik Haagensen
Bradford A. Mehldau & Fleurine E. Verloop-Mehldau
Scott W. Morgan & Fred Hersch
Laura A. Morrison
National Convention Services/Debra Hoefler
Scott Newman
Trang M. Ngo
Donna M. Pauldine "In Memory of Jeff Palladino"
Pamela Perkins
Daphne Powell & Christopher Harrington
Frank Rappa
Daryl Roth
Edward "Ned" Rothenberg & Lois Ellison
Peter A. Schamel "In Memory of Ray Steinman"
Betty C. Sikov
Samuel J. Silling
Jane Silver
Margie & Mort Steinberg "In Honor of Leslie Zackman"
Derek S. Tarson
Keith S. Tobin, MD
Dr. Peter C. Walter & David N. Zane, Esq.
Frederick Werthiem
P. Forrest Williams
Mark Wyn
Anthony Zisa

In-Kind Donations

Jonathan Adler
A|X Armani Exchange
Comfort Foods/Project Renewal
Keith Haring Foundation
it's the watsons
Lärabar
J. Lohr Vineyards & Wines
POZ Magazine
Santa Alicia Vineyards & Winery
WHWest Inc.
Zomba Records

The Palm Donor Circle

Special Recognition by TAG

The Palm Donor Circle of the Treatment Action Group is TAG's major donor program, named in honor of philanthropist and TAG supporter Michael Palm (1951-1998). Members of the Palm Donor Circle made individual donations of \$1,000 or more to TAG in 2009.

Henry H. Arnhold
Carl Berg PhD & Judith Green PhD
Helen Bodian & Roger Alcala
Timothy & Mary C. Casey
David Corkery
Edgar M. & Elissa F. Cullman
Nicholas A.R. Debs
Richard A. & Barbara Knowles Debs
Randall G. Drain
Marcus Edward & Ken O'Neill
M. Lee Garrison
Dr. Michael F. Giordano
Steven & Judith O. Gluckstern
Agnes Gund
William Haber
Brian Hargrove & David Hyde Pierce
Judith & Richard Harrington
Florette B. Hoffheimer
Barbara F. Hughes &
Andrea Benzacar Dailey
Horace S. "Chad" Kenney III
Noel E.D. Kirnon & Michael D. Paley
Richard M. Lynn & Joseph Evall
Alby P. Maccarone, Jr.

Stephen Mack & Robert Monteleone
James S. & Ellen Marcus
Barry Margolin
Terence S. & Emily Souvaine Meehan
Kenneth T. Monteiro & Leo J. Blackman
Kent & Ann Morgan
Stuart & Linda Nelson
Jason I. Osher & Richard R. Schubel
Andrew & Andrea Potash
Walter Rieman
James Saakvitne & Daniel Chow
David Saylor & Charles Kreloff
Dr. Bruce R. Schackman &
Edward K. Sikov
Evan Schwartz & Robert Fitterman
Marvin Shulman
David Sigal & Brad Hoylman
Gerald & Ellen Sigal
Frank E. Spring & Darrel Frost
Monte Steinman
W. Kirk Wallace & Mark M. Sexton
Terry K. Watanabe
Simon Yates & Kevin Roon
Andrew David Zacks

TAG BE INVOLVED

About TAG

Treatment Action Group is an independent AIDS research and policy think tank fighting for better treatment, a vaccine, and a cure for AIDS. TAG works to ensure that all people with HIV receive lifesaving treatment, care, and information. We are science-based treatment activists working to expand and accelerate vital research and effective community engagement with research and policy institutions. TAG catalyzes open collective action by all affected communities, scientists, and policy makers to end AIDS.

Program areas include AIDS policy issues, antiretroviral treatment, basic science, vaccines, viral hepatitis, and tuberculosis.

Join TAG's Board

TAG is always seeking new board members. If you are looking for a great place to invest your time and talents, please call Barbara Hughes, TAG board president, to learn more about board opportunities with TAG.

212.253.7922
barbara.hughes@treatmentactiongroup.org

Contribute!

TAG welcomes donations from individuals who want to see the AIDS research agenda remain responsive to the needs of all people living with HIV.

To make a charitable donation to TAG, call 212.253.7922 or go online to www.treatmentactiongroup.org.

BOARD OF DIRECTORS

PRESIDENT
Barbara Hughes

**SECRETARY &
TREASURER**
Laura Morrison

Joy Episalla
Kevin Goetz
Richard Lynn, Ph.D.
Alby P. Maccarone, Jr.
Robert Monteleone
Jason Osher
Frank Rappa
David Sigal
James Saakvitne
Monte Steinman

EXECUTIVE DIRECTOR
Mark Harrington

DEPUTY DIRECTOR
Scott W. Morgan, MPA

POLICY DIRECTOR
Sue Perez, MPH

SENIOR POLICY ASSOCIATE
Coco Jervis, JD

**BASIC SCIENCE, VACCINES
AND PREVENTION:**
MICHAEL PALM PROJECT
COORDINATOR
Richard Jefferys

**HEPATITIS/HIV PROJECT
DIRECTOR**
Tracy Swan

HEPATITIS/HIV COORDINATOR
Lei Chou

TB/HIV PROJECT DIRECTOR
Javid Syed, MPH

TB/HIV PROJECT ASSISTANT DIRECTOR
Claire Wingfield, MPH

ADMINISTRATOR
Joseph McConnell

Treatment Action Group

611 Broadway, Suite 308
New York, NY 10012
Tel 212.253.7922, Fax 212.253.7923
tag@treatmentactiongroup.org
www.treatmentactiongroup.org

TAG is a nonprofit, tax-exempt 501(c)(3) organization. E.I.N. 13-3624785

TAG

Treatment Action Group

TAG FINANCIALS 2009

STATEMENTS OF FINANCIAL POSITION

Assets

Current assets:

Cash and cash equivalents

Contributions receivable

Prepaid expenses and other receivables

TOTAL CURRENT ASSETS

Property and equipment—net of accumulated depreciation

Security deposits

TOTAL ASSETS

Year ended December 31

2009

2008

\$ 1,425,566	\$ 1,350,325
1,040,096	1,253,097
10,718	14,974
2,476,380	2,618,396
51,283	57,961
20,654	20,654
\$ 2,548,317	\$ 2,697,011

Liabilities and Net Assets

Current liabilities

Accounts payable and accrued expenses

TOTAL LIABILITIES
Net assets

Unrestricted

Temporarily restricted

TOTAL NET ASSETS
TOTAL LIABILITIES AND NET ASSETS

\$ 16,142	\$ 2,630
16,142	2,630
1,270,302	1,126,049
1,261,873	1,568,332
2,532,175	2,694,381
\$ 2,548,317	\$ 2,697,011

Statement of Cash Flows

Cash flows from operating activities:

Increase (Decrease) in net assets

Adjustments to reconcile increase in net assets
to net cash provided by operating activities:

Depreciation

(Increase) Decrease in current assets:

Contributions receivable

Prepaid expenses and other receivables

Security deposits

(Decrease) Increase in current liabilities:

Accounts payable and accrued expenses

NET CASH (USED IN) PROVIDED BY OPERATING ACTIVITIES
Cash flows from investing activities:

Purchases of property and equipment

Net cash used in investing activities

Net decrease (increase) in cash balance

CASH, BEGINNING OF YEAR

CASH, END OF YEAR

\$ (162,206)	\$ (100,153)
16,099	14,352
213,001	733,303
4,256	84,632
-	-
13,512	(4,424)
\$ 84,662	\$ 727,710
(9,421)	(28,574)
(9,421)	(28,574)
75,241	699,136
1,350,325	651,189
\$ 1,425,566	\$ 1,350,325

TAG FINANCIALS 2009

STATEMENTS OF ACTIVITIES

	Unrestricted	Temporarily Restricted	Year ended December 31	
			2009	2008
Revenue and support:				
Direct mail	\$ 36,432	\$ -	\$ 36,432	\$ 44,340
Donations	50,965	-	50,965	29,427
Grants	351,600	1,301,232	1,652,832	1,682,807
Special-event income	188,042	-	188,042	159,151
Travel and other reimbursement	32,631	-	32,631	40,159
Interest and dividend income	7,330	-	7,330	31,654
	<u>667,000</u>	<u>1,301,232</u>	<u>1,968,232</u>	<u>1,987,538</u>
Net assets released from restrictions	1,607,691	(1,607,691)	-	-
TOTAL REVENUE AND SUPPORT	2,274,691	(306,459)	1,968,232	1,987,538
Expenses:				
Program Services				
Antiretroviral Project	77,780	-	77,780	53,147
Michael Palm HIV Pathogenesis and Prevention Project	224,907	-	224,907	157,086
Hepatitis/HIV Project	300,233	-	300,233	263,452
TB/HIV Advocacy Project	1,241,677	-	1,241,677	1,259,987
U.S and Global Health Policy Project	47,530	-	47,530	99,952
Communications	14,134	-	14,134	79,298
TOTAL PROGRAM EXPENSES	1,906,261	-	1,906,261	1,912,922
Management and general	131,481	-	131,481	98,316
Fund-raising	92,696	-	92,696	76,453
TOTAL SERVICES EXPENSES	2,130,438	-	2,130,438	2,087,691
Increase in net assets	144,253	(306,459)	(162,206)	(100,153)
Net assets, beginning of year	1,126,049	1,568,332	2,694,381	2,794,534
NET ASSETS, END OF YEAR	1,270,302	1,261,873	2,532,175	2,694,381

SUMMARY OF 2009 FUNCTIONAL EXPENSES

